Bristol-Myers Squibb Co. has reviewed the value of its pending $74bn acquisition of Celgene Corp. for several months and believes – contrary to the views of some of its biggest investors – that the combined companies offer much more value to shareholders than either entity on its own.
Bristol released a letter to its shareholders and an investor presentation defending the deal on March 6 as materials to...








